.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,846,086

« Back to Dashboard

Details for Patent: 8,846,086

Title:Tamper resistant dosage forms
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Inventor(s): McKenna; William H. (Yonkers, NY), Mannion; Richard O. (Furlong, PA), O'Donnell; Edward P. (Basking Ridge, NJ), Huang; Haiyong H. (Princeton, NJ)
Assignee: Purdue Pharma L.P. (Stamford, CT)
Filing Date:May 23, 2013
Application Number:13/901,047
Claims:1. A convection cured shaped tablet comprising an extended release matrix comprising a composition, wherein said tablet comprises: (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000, and (2) hydromorphone or a pharmaceutically acceptable salt, and wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend to form a shaped tablet; and (c) convection curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 8 hours, wherein said convection cured shaped tablet comprises at least 79% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000.

2. A convection cured shaped tablet as defined in claim 1, wherein said hydromorphone or pharmaceutically acceptable salt is hydromorphone hydrochloride.

3. A convection cured shaped tablet as defined in claim 1, wherein said time in said curing step is 30 minutes to 90 minutes.

4. A convection cured shaped tablet as defined in claim 1, wherein said temperature in said curing step is from 62 to 90.degree. C.

5. A convection cured shaped tablet as defined in claim 1, wherein said shaped tablet is coated before or after said curing step.

6. A convection cured shaped tablet as defined in claim 1, wherein said convection cured shaped tablet comprises a once-a-day dosage form.

7. A convection cured shaped tablet as defined in claim 1, wherein said convection cured shaped tablet comprises a twice-a-day dosage form.

8. A convection cured shaped tablet as defined in claim 1, wherein said tablet is shaped by compression.

9. A convection cured shaped tablet as defined in claim 1, wherein the density of the extended release matrix of said convection cured shaped tablet is lower than the density of the extended release matrix of said shaped tablet prior to curing.

10. A convection cured shaped tablet comprising an extended release matrix comprising a composition, wherein said tablet comprises: (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000, and (2) hydromorphone hydrochloride; wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend to form a shaped tablet; and (c) convection curing said shaped tablet by subjecting the shaped tablet to a temperature from about 60 to about 90.degree. C. for a time of from about 15 minutes to about 10 hours, wherein said convection cured shaped tablet comprises: (i) one of 8 mg, 12 mg, and 32 mg hydromorphone hydrochloride; and (ii) at least about 90% by weight, based upon the total weight of said composition, of said at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000.

11. A convection cured shaped tablet as defined in claim 10, wherein the density of the extended release matrix of said convection cured shaped tablet is lower, by at least 0.5%, than the density of the extended release matrix of said shaped tablet prior to curing.

12. A convection cured shaped tablet as defined in claim 10, wherein the tablet comprises: (1) 8 mg hydromorphone hydrochloride and at least about 94% of said polyethylene oxide by weight, based upon the total weight of said composition; (2) 12 mg hydromorphone hydrochloride and at least about 92% of said polyethylene oxide by weight, based upon the total weight of said composition; or (3) 32 mg hydromorphone hydrochloride and at least about 90% of said polyethylene oxide by weight, based upon the total weight of said composition.

13. A convection cured shaped tablet as defined in claim 10, wherein, said temperature in said curing step is from 62 to 90.degree. C.

14. A convection cured shaped tablet as defined in claim 10, wherein said tablet is shaped by compression.

15. A convection cured shaped tablet as defined in claim 10, wherein the tablet comprises 8 mg hydromorphone hydrochloride and at least about 94% of said polyethylene oxide by weight, based upon the total weight of said composition.

16. A convection cured shaped tablet as defined in claim 10, wherein the tablet comprises 12 mg hydromorphone hydrochloride and at least about 92% of said polyethylene oxide by weight, based upon the total weight of said composition.

17. A convection cured shaped tablet as defined in claim 10, wherein the tablet comprises 32 mg hydromorphone hydrochloride and at least about 90% of said polyethylene oxide by weight, based upon the total weight of said composition.

18. A convection cured shaped tablet as defined in claim 10, wherein the tablet comprises 12 mg hydromorphone hydrochloride and at least about 92% of said polyethylene oxide by weight, based upon the total weight of said composition.

19. A convection cured shaped tablet as defined in claim 10, wherein the tablet comprises 32 mg hydromorphone hydrochloride and at least about 90% of said polyethylene oxide by weight, based upon the total weight of said composition.

20. A convection cured shaped tablet comprising an extended release matrix comprising a composition, wherein said tablet comprises: (1) at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 4,000,000 and (2) hydromorphone hydrochloride; wherein said tablet is prepared by a process comprising the steps of: (a) combining at least (1) and (2) to form a blend; (b) shaping said blend to form a shaped tablet; and (c) convection curing said shaped tablet by subjecting the shaped tablet to a temperature from 62 to 90.degree. C. for a time of from about 30 minutes to about 8 hours, wherein said convection cured shaped tablet comprises: (i) 8 mg hydromorphone hydrochloride and at least about 94% of said polyethylene oxide by weight, based upon the total weight of said composition; (ii) 12 mg hydromorphone hydrochloride and at least about 92% of said polyethylene oxide by weight, based upon the total weight of said composition; or (iii) 32 mg hydromorphone hydrochloride and at least about 90% of said polyethylene oxide by weight, based upon the total weight of said composition.

21. A convection cured shaped tablet as defined in claim 20, wherein said time in said curing step is 30 minutes to 90 minutes.

22. A convection cured shaped tablet as defined in claim 21, wherein said shaped tablet is coated before or after said curing step.

23. A convection cured shaped tablet as defined in claim 20, wherein said tablet comprises 8 mg hydromorphone hydrochloride and at least about 94% of said polyethylene oxide by weight, based upon the total weight of said composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc